CITIUS PHARMAC. DL -001
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related… Read more
CITIUS PHARMAC. DL -001 (47N) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CITIUS PHARMAC. DL -001 (47N) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CITIUS PHARMAC. DL -001 - Net Assets Trend (None–None)
This chart illustrates how CITIUS PHARMAC. DL -001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CITIUS PHARMAC. DL -001 (None–None)
The table below shows the annual net assets of CITIUS PHARMAC. DL -001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CITIUS PHARMAC. DL -001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CITIUS PHARMAC. DL -001 Competitors by Market Cap
The table below lists competitors of CITIUS PHARMAC. DL -001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Harris Technology Group Ltd
AU:HT8
|
$1.04 Million |
|
KRAŠ d.d.
ZSE:KRAS
|
$1.04 Million |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
$1.04 Million |
|
EAST AFRICA RES
F:NM1
|
$1.04 Million |
|
EARTHS Energy Ltd
AU:EE1
|
$1.04 Million |
|
Amixa Holding Nyrt
BUD:AMIXA
|
$1.04 Million |
|
Eka Sari Lorena Transport Tbk
JK:LRNA
|
$1.04 Million |
|
Klil Industries Ltd
TA:KLIL
|
$1.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CITIUS PHARMAC. DL -001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CITIUS PHARMAC. DL -001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CITIUS PHARMAC. DL -001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CITIUS PHARMAC. DL -001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CITIUS PHARMAC. DL -001 (47N) | €- | N/A | N/A | $1.04 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |